{"title":"Dosimetric risk factors for therapy-related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy.","authors":"Ying Lu, Youjia Wang, Guang Han, Jianping Bi, Guoliang Pi, Xinbin Pan, Vivek Verma, Xiaofang Dai, Jiangqiong Huang, Ying Li","doi":"10.1002/pro6.70102","DOIUrl":"10.1002/pro6.70102","url":null,"abstract":"<p><strong>Objective: </strong>Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively investigated to improve clinical outcomes; however, this strategy may also increase the risk of treatment-related toxicities. This multicenter study aimed to identify clinical and dosimetric predictors of treatment-related pneumonitis (TRP) in this patient population, focusing on modifiable predictors of toxicity.</p><p><strong>Methods: </strong>A retrospective review was conducted on 69 patients with lung or esophageal cancer treated at three hospitals. All patients received concurrent ICIs, chemotherapy, and thoracic radiotherapy at a dose of 50-60 Gy (in 2 Gy fractions) using inverse-planned techniques. TRP was graded according to the Common Terminology Criteria for Adverse Events version 5.0. Logistic regression modeling and receiver operating characteristic (ROC) analysis were employed for statistical evaluation.</p><p><strong>Results: </strong>Any-grade TRP occurred in 56.5% of patients. Grade 2-5 TRP occurred in 30.4%, 8.7%, 1.4%, and 0% of patients, respectively. Age (<i>p </i>= 0.01; <i>OR </i>= 1.1) and mean lung dose (MLD) (<i>p </i>= 0.02; <i>OR </i>= 2.4) independently contributed to the risk of any-grade TRP. Age (<i>p </i>= 0.03; <i>OR </i>= 1.1) and MLD (<i>p </i>= 0.04; <i>OR </i>= 1.7) were also identified as risk factors for grade 2+ TRP. Other parameters, such as lung <i>V</i>5, <i>V</i>10, <i>V</i>15, <i>V</i>20, and <i>V</i>30 were not significantly associated with TRP. ROC analysis identified 13.6 Gy as the optimal MLD threshold for predicting both any-grade and grade 2+ TRP.</p><p><strong>Conclusions: </strong>MLD and age were associated with a higher risk of TRP in patients receiving concurrent chemoradiotherapy and ICIs. These findings may help inform revisions to lung dose constraints, although validation in large-scale prospective trials is warranted.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eva Birring, Yao Zhao, Tze Yee Lim, Mustefa Mohammedsaid, Neil Hughes, Cameron Tharp, JaRhonda Tealer, Ruitao Lin, Comron Hassanzadeh, C David Fuller, Jinzhong Yang
{"title":"Evaluation of Concordance between Radiation Therapists and Medical Physicists in MR-Guided Online Adaptive Planning.","authors":"Eva Birring, Yao Zhao, Tze Yee Lim, Mustefa Mohammedsaid, Neil Hughes, Cameron Tharp, JaRhonda Tealer, Ruitao Lin, Comron Hassanzadeh, C David Fuller, Jinzhong Yang","doi":"10.1002/pro6.70105","DOIUrl":"https://doi.org/10.1002/pro6.70105","url":null,"abstract":"<p><strong>Purpose: </strong>Magnetic resonance (MR) -guided online adaptive radiotherapy requires skill in online adaptive treatment planning. The aim of this study was to demonstrate that radiation therapists, with appropriate training, can consistently produce high-quality adaptive plans concordant with those created by medical physicists for treatment on a 1.5 Tesla MR-Linac (MRL).</p><p><strong>Methods: </strong>We evaluated plans generated by two experienced MRL radiation therapists and two MR-Linac medical physicists using an adapt-to-position (ATP) workflow to treat 10 patients with head and neck cancer; this workflow includes an iso-center shift and plan re-optimization to account for setup discrepancy between simulation and treatment. For each adaptive session, CT-MR images were fused and isocenter translational shifts recorded. Differences among the three roles (Therapist, Physicist 1, Physicist 2) were assessed by repeated-measures analysis of variance (RM-ANOVA) and Bonferroni-corrected post-hoc paired t tests, reported as secondary, exploratory analyses. Agreement on shifts and dosimetric endpoints was quantified with Lin's concordance correlation coefficient (CCC), with bias-corrected and accelerated bootstrap 95% confidence intervals (CIs), as the primary analysis.</p><p><strong>Results: </strong>No significant differences were observed among roles for X- or Y-axis shifts (<i>p</i> = 0.804 and <i>p</i> = 0.950). A statistically significant difference was observed for Z-axis shifts (<i>p</i> = 0.005), driven by Therapist versus Physicist 1 (Bonferroni-adjusted <i>p</i> = 0.015; mean paired difference 0.10 cm, 95% CI 0.04-0.17 cm), a systematic difference of approximately 1 mm that is small relative to clinical planning margins. CCC point estimates were 0.866-0.970 for translational shifts and 0.972-0.997 for target coverage and maximum dose, with no point estimate in the poor-agreement range (CCC < 0.80). Bootstrap 95% CIs were wide for the shifts, as expected at n = 10, but therapist-physicist agreement was comparable to physicist-physicist agreement for every endpoint, and CI lower bounds for the dosimetric endpoints were ≥0.75 (maximum dose ≥0.97).</p><p><strong>Conclusion: </strong>Our results showed good concordance between adaptive plans created by radiation therapists and medical physicists in the ATP workflow for head and neck cancer, suggesting that appropriately trained therapists can produce high-quality adaptive plans in this specific context. These conclusions are limited to the ATP workflow and to head and neck cancer; extension to other sites or to the adapt-to-shape (ATS) workflow requires independent investigation.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149274195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linzheng Hu, Yongkang Zhao, Chunling Zheng, Jiajun Cai, Yajun Jia, Yi Tao, Yikun Liu, Yin Zhang, Zhitao Dai
{"title":"Implementation and preliminary evaluation of a practical digital workflow for routine laser-radiation field coincidence quality assurance on the CyberKnife M6.","authors":"Linzheng Hu, Yongkang Zhao, Chunling Zheng, Jiajun Cai, Yajun Jia, Yi Tao, Yikun Liu, Yin Zhang, Zhitao Dai","doi":"10.1002/pro6.70103","DOIUrl":"https://doi.org/10.1002/pro6.70103","url":null,"abstract":"<p><strong>Purpose: </strong>To implement and preliminarily evaluate a practical digital acquisition-and-analysis workflow for routine laser-radiation field coincidence quality assurance (QA) on the CyberKnife M6 by integrating multileaf collimator (MLC) QA tool-based laser reference definition, QA StereoChecker (QASC)-based external digital image acquisition, and automated analysis with CKQA, an in-house CyberKnife QA software, and to compare this workflow with clinically realistic film-based alternatives.</p><p><strong>Methods: </strong>Methods a and b were film-based measurements performed at the perch position. Method a used manual laser marking on film, whereas method b used the central metal marker of the MLC QA tool to define the laser reference. Method c used QASC as an external digital image-acquisition platform in combination with the MLC QA tool, and method d used film on the same QASC-based setup as a control. All methods were tested with 10 fixed collimators (5-40 mm). Images were analyzed using ImageJ and CKQA. Mean deviation, standard deviation, root mean square error (RMSE), and pairwise two-sided exact Wilcoxon signed-rank tests were used for exploratory comparisons.</p><p><strong>Results: </strong>All evaluated workflows achieved submillimeter mean deviations. Across both analysis approaches, the mean deviation ranked consistently in descending order: method a > method b > method d > method c. Under the present experimental conditions, method c yielded the lowest mean deviation and RMSE (0.116 mm and 0.155 mm with CKQA), whereas method a showed the largest deviations. Dataset-level exact Wilcoxon signed-rank tests showed that several comparisons involving method a were statistically significant, but statistically significant differences were not uniform across both ImageJ- and CKQA-based comparisons. For comparisons between analysis methods within each workflow, CKQA and ImageJ were not significantly different for methods a and b, whereas CKQA yielded significantly lower deviations than ImageJ for methods c and d (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Laser-radiation field coincidence testing is an established CyberKnife QA procedure. The present study implemented and preliminarily evaluated a practical digital acquisition-and-analysis workflow for this routine task. The workflow combining MLC QA tool-based laser reference definition, QASC-based external digital image acquisition, and automated CKQA analysis provided a standardized and less operator-dependent procedure under the present experimental conditions. Its main value lies in reducing manual marking, film handling, scanning, and subjective image-analysis steps rather than in introducing a new physical measurement principle. In centers where QASC is not available, the film-based workflow using the MLC QA tool (method b) may serve as a practical alternative.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149274188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annalisa Muscato, Denis La Fauci, Anna Viola, Valentina Zagardo, Gianluca Ferini
{"title":"Feasibility of Urethra-Sparing Ultra-Hypofractionated Three-Dose-Level Radiotherapy for Prostate Cancer with a Dominant Intraprostatic Lesion Abutting the High-Dose Avoidance Zone.","authors":"Annalisa Muscato, Denis La Fauci, Anna Viola, Valentina Zagardo, Gianluca Ferini","doi":"10.1002/pro6.70104","DOIUrl":"https://doi.org/10.1002/pro6.70104","url":null,"abstract":"<p><p>This planning study evaluated ultra-hypofractionated three-dose-level radiotherapy for prostate cancer with a dominant intraprostatic lesion (DIL) abutting the urethral high-dose avoidance zone (HDAZ). Ten patients (30 volumetric modulated arc therapy [VMAT] plans) were re-planned with 25 Gy to the pelvis, 35 Gy to the prostate, and 50 Gy to the DIL in five fractions. All plans achieved coverage while keeping urethral doses below the 90 GyEQD2 threshold and meeting organ-at-risk constraints, irrespective of DIL size or HDAZ contact. The findings demonstrate the feasibility of urethra-sparing with effective DIL dose escalation, even in peri-HDAZ locations.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149274205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xingliang Liu, Gang Wang, Zhenwen Zhao, Haoyu Wang, Hongyu Chen, Xiao Xu, Jingdong Li, Hongjuan Ma
{"title":"<sup>177</sup>Lu-labeled amidoxime-functionalized biodegradable microspheres for transarterial radioembolization of hepatocellular carcinoma.","authors":"Xingliang Liu, Gang Wang, Zhenwen Zhao, Haoyu Wang, Hongyu Chen, Xiao Xu, Jingdong Li, Hongjuan Ma","doi":"10.1002/pro6.70094","DOIUrl":"10.1002/pro6.70094","url":null,"abstract":"<p><strong>Purpose: </strong>Transarterial radioembolization (TARE) is an important locoregional therapy for hepatocellular carcinoma (HCC). However, clinically used yttrium-90 (<sup>90</sup>Y) microspheres are non-biodegradable and provide limited imaging capability, while biodegradable polymeric microspheres prepared using conventional radiolabeling strategies often exhibit poor radionuclide stability.</p><p><strong>Experimental design: </strong>We designed a biodegradable radiometal-chelating microsphere based on amidoxime-functionalized polylactic acid microspheres (PLA-g-PAO-Ms) engineered via electron beam-induced graft polymerization.</p><p><strong>Results: </strong>The PLA-g-PAO-Ms exhibited a high Lu<sup>3+</sup> loading capacity (33.83 mg g<sup>-1</sup>) and underwent controlled biodegradation in vitro after approximately 20 d. Cell Counting Kit-8 (CCK-8) assays confirmed favorable cytocompatibility, with both LO2 and HepG2 cell viabilities exceeding 90% after 72 h, showing no significant difference from the control group (<i>p</i> > 0.05); by contrast, free Lu<sup>3+</sup> (50 mg·L<sup>-1</sup>) significantly reduced HepG2 viability to 51.4% (<i>p</i> < 0.001). In a rat orthotopic liver tumor model, the intra-arterial administration of <sup>177</sup>Lu-labeled PLA-g-PAO-Ms (<sup>177</sup>Lu-PLA-g-PAO-Ms) resulted in pronounced tumor suppression with sustained in vivo radionuclide retention for at least 14 d. Biodistribution analysis revealed selective tumor accumulation of <b>8.79 ± 1.74 %ID g<sup>-1</sup></b> , significantly higher than that in normal liver (<b>1 ± 0.54 %ID g<sup>-1</sup></b> ) and other organs (<b> <i>P</i>< 0.001</b>), whereas free <sup>177</sup>LuCl<sub>3</sub> showed minimal tumor uptake (<b>0.30 ± 0.28 %ID g<sup>-1</sup></b> ) with predominant non-target organ accumulation.</p><p><strong>Conclusion: </strong>These findings suggest that PLA-g-PAO-Ms provide a biodegradable microsphere system capable of stable radiometal incorporation and effective tumor suppression following intra-arterial administration, offering a promising approach for interventional radionuclide therapy for HCC.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13621439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Integrated multi-omics analysis of post-translational modifications in head and neck squamous cell carcinoma: elucidating x-ray and carbon ion irradiation effects.","authors":"Fan-Tong Xia, Zhi-Yun Liao, Si-Qi Cai, Li-Rong Zhou, Meng-Qi Yang, Xin Zhang, Dan Li, Huan Zhang, Yun-Chang Liu, Jie-Ying Yang, Jia Jiang, Yi-Hong Hu, Jiang-Dong Sui, Ying Wang","doi":"10.1002/pro6.70097","DOIUrl":"10.1002/pro6.70097","url":null,"abstract":"<p><strong>Background and purpose: </strong>Head and neck squamous cell carcinoma (HNSCC) exhibits heterogeneous responses to radiotherapy; however, the underlying multi-omics regulatory networks remain poorly characterized. This study elucidated the distinct post-translational modification (PTM) landscapes induced by X-ray and carbon-ion irradiation.</p><p><strong>Methods: </strong>Using integrated proteomics, phosphoproteomics, and acetylomics, we systematically profiled PTMs in HSC-3 cells at 30 min post-irradiation with X-ray (8 Gy) or carbon ions (4 GyE). Computational analyses included functional annotation, kinase activity prediction, and PTM crosstalk mapping.</p><p><strong>Results: </strong>Carbon ions induced 21% more phosphosites (2,781 vs. 2,301) and 61% more acetyl sites (3,324 vs. 2,070) than X-ray, demonstrating broader PTM reprogramming. Notably, carbon ion-induced histone hypoacetylation (H2AZ1K8/K5, H3C1K28/K24, and H4C1K92) and hyperphosphorylation (H1-10S2 and H3C1T119) potentially alter chromatin accessibility. Functional enrichment analyses revealed the activation of the non-homologous end-joining (NHEJ) pathway and coordinated upregulation of antigen-presenting machinery (such as CD274, TAP2, HLA-A, and PSMB8) through PTM remodeling. Distinct PTM signatures in RNA splicing factors implicate alternative splicing in radiation response. Kinase activity profiling revealed ATM hyperactivation and CDK suppression in the carbon ion group.</p><p><strong>Conclusions: </strong>Carbon ion irradiation drives distinct PTM-mediated immunomodulatory and DNA damage-response networks, providing a mechanistic rationale for combining carbon ion radiotherapy with immunotherapy. Future studies should validate the PTM-associated targets to improve HNSCC treatment.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high-risk patients with locally advanced head and neck squamous cell carcinoma post-surgery: A real-world study.","authors":"Yuejia Zhou, Linting Zhang, Wenjuan Lai, Jingyun Tan, Jing Gao, Yajie Liu, Shubin Wang, Feng Peng, Gangling Tong","doi":"10.1002/pro6.70099","DOIUrl":"10.1002/pro6.70099","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) harboring high-risk pathological features after radical surgery face high recurrence rates. This real-world study evaluated the efficacy and safety of concurrent chemoradiotherapy (CCRT) with and without nimotuzumab in this postoperative population.</p><p><strong>Methods: </strong>Patients with LA-HNSCC who had high-risk pathological features after surgery were stratified as follows: those with extranodal extension (ENE) or positive/insufficient margins received nimotuzumab plus CCRT (NCCRT; extremely high risk), whereas those with other high-risk factors (e.g., pT3-4 and N2-3) received CCRT alone (intermediate high risk). All patients underwent intensity-modulated radiotherapy with weekly cisplatin. Overall survival (OS) was the primary endpoint, and event-free survival (EFS) and safety were secondary endpoints. To minimize confounding bias due to non-randomized treatment allocation, propensity-score matching (PSM) was performed using a 1:1 nearest neighbor matching algorithm with a caliper width of 0.2 times the standard deviation of the propensity score.</p><p><strong>Results: </strong>A total of 75 patients were enrolled in this study (CCRT, n = 50; NCCRT, <i>n</i> = 25). After PSM, 22 well-balanced pairs were identified with no significant differences in baseline characteristics between the two groups. The median follow-up time was 29.80 months (95% confidence interval [<i>CI</i>]: 25.83-33.77) in the CCRT group and 30.23 months (95% <i>CI</i>: 25.07-35.40) in the NCCRT group. In the overall cohort, the 2-year EFS and OS rates were 74.1% vs 60.6% and 85.6% vs 83.6%, respectively. In the matched cohort, the 2-year EFS and OS rates were 73.8% vs 58.3% (log-rank <i>p</i> = 0.087) and 86.2% vs 82.5% (log-rank <i>p</i> = 0.342), respectively. Univariate analysis revealed that the platelet-to-lymphocyte ratio (PLR) and hemoglobin-albumin-lymphocyte-platelet (HALP) score were significantly associated with OS in the CCRT group (<i>p</i> = 0.019 and <i>p</i> = 0.009, respectively). Treatment-related adverse events were predominantly grades 1-2, including radiodermatitis, oral mucositis, and hematological toxicities, with no significant increase in severe toxicities in the NCCRT group.</p><p><strong>Conclusions: </strong>Risk-stratified adjuvant CCRT, with or without nimotuzumab, was associated with promising outcomes and acceptable safety in patients with high-risk postoperative LA-HNSCC. Thus, PLR and HALP may serve as candidate prognostic biomarkers for intermediate-risk patients and warrant further validation. These findings are hypothesis-generating and require confirmation in prospective randomized studies with dedicated control groups.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hui Luo, Chen Cheng, Chengliang Yang, Bing Li, Jiandong Zhang, Jinbo Yue, Zhaoyang Lou, Hui Liu, Jing Cai, Hong Ge
{"title":"Expert consensus on clinical trial design guidelines for FLASH radiotherapy.","authors":"Hui Luo, Chen Cheng, Chengliang Yang, Bing Li, Jiandong Zhang, Jinbo Yue, Zhaoyang Lou, Hui Liu, Jing Cai, Hong Ge","doi":"10.1002/pro6.70098","DOIUrl":"https://doi.org/10.1002/pro6.70098","url":null,"abstract":"<p><p>In recent years, ultra-high dose-rate FLASH radiotherapy (FLASH-RT) has emerged as a prominent research focus in radiation oncology. A series of preclinical data indicate that FLASH-RT can achieve tumor-killing efficacy that is not inferior to that of conventional radiotherapy (CONV-RT) while significantly reducing radiation damage to normal tissues. This distinctive tissue-sparing effect is known as the \"FLASH effect.\" Rapid progress has been made in the clinical translation and application of FLASH-RT. Against this backdrop, the China Anti-Cancer Association Radiation Oncology Committee and the Chinese Medical Doctor Association Radiation Oncology Physician Committee gathered a group of experts and compiled the \"Expert Consensus on Clinical Trial Design Guidelines for FLASH Radiotherapy\" based on the latest domestic and international research advancements. This document summarizes the latest advances in FLASH-RT and offers practical guidance for its design and translational application in future clinical trials.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xin Wang, Tze Yee Lim, He Wang, Bouthaina Shbib Dabaja, Jinzhong Yang
{"title":"MR-Linac Successfully Guided the Treatment of a Free-Moving Mesenteric Mass.","authors":"Xin Wang, Tze Yee Lim, He Wang, Bouthaina Shbib Dabaja, Jinzhong Yang","doi":"10.1002/pro6.70093","DOIUrl":"10.1002/pro6.70093","url":null,"abstract":"<p><p>A patient presenting with stage I follicular lymphoma was dispositioned for a definitive and curative radiation treatment. The tumor had significant daily movement, as much as 3.83, 3.26 and 12.42 cm in the anterior-posterior, superior-inferior and left-right direction respectively. The tumor volume increased from 16.72 to 44.23 cc in first 5 fractions, followed by a downward trend. To account for the inter-fraction tumor motion, online adaptive radiation therapy was delivered using Elekta Unity MR-Linac. Each fraction, the treating physician manually delineated the planning target volume (PTV) and Unity successfully generated an optimum adaptive plan with PTV coverage ≥ 95%. This case demonstrated that MR-Linac online adaptive workflow was superior in treating a free-moving and volume changing mesenteric mass, minimizing the margin needed in conventional static plan to cover the unpredictable large daily shift.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Keru Pu, Tengxiang Li, Shengnan Xu, Xue Sha, Qingtao Qiu, Jinming Yu, Yong Yin, Jie Liu
{"title":"C-X-C Motif Chemokine Receptor 4 (CXCR4)-Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited-Stage Small Cell Lung Cancer.","authors":"Keru Pu, Tengxiang Li, Shengnan Xu, Xue Sha, Qingtao Qiu, Jinming Yu, Yong Yin, Jie Liu","doi":"10.1002/pro6.70095","DOIUrl":"10.1002/pro6.70095","url":null,"abstract":"<p><strong>Background and purpose: </strong>To evaluate the feasibility and dosimetric safety of integrating C-X-C motif chemokine receptor 4 (CXCR4)-targeted tracer <sup>1</sup> <sup>8</sup>F-AlF-NOTA-QHY-04 positron emission tomography imaging with biologically guided proton spatially fractionated radiotherapy (BG-pSFRT) for bulky limited-stage small cell lung cancer.</p><p><strong>Materials and methods: </strong>Among 30 patients with bulky limited-stage small-cell lung cancer, a threshold range of 35%-40% of the maximum standard uptake value (SUV<sub>max</sub>) showed optimal spatial correspondence with the computed tomography-based gross tumor volume (GTV). The median SUV<sub>max</sub> was 6.96, and the Dice similarity coefficient ranged from 0.707 to 0.723. CXCR4-avid sub-volumes within GTV were characterized against the sub-targets of stereotactic body radiotherapy based partial tumor irradiation targeting hypoxic segments (SBRT-PATHY) and stereotactic centralized ablative radiation therapy (SCART). Dosimetric comparisons were performed between the BG-pSFRT and SCART plans (15-24 Gy per fraction in three fractions).</p><p><strong>Results: </strong>CXCR4-defined sub-volumes with low thresholds in BG-pSFRT demonstrated spatial concordance with putative hypoxic sub-volumes in SBRT-PATHY, whereas higher SUV<sub>max</sub> thresholds yielded multifocal distributions that exhibited spatial discordance relative to SCART, and these multifocal imaging-defined sub-volumes were targeted in BG-pSFRT for dose escalation. Compared to proton SCART, BG-pSFRT achieved greater high-dose (V<sub>80%</sub>), GTV coverage but slightly lower sub-volume conformity (89.04% vs. 95.55%; <i>P</i> < 0.001), and higher V<sub>5Gy</sub> and dose per fraction (<i>P</i> < 0.001). All organ-at-risk doses met the standard 3-fraction SBRT constraints.</p><p><strong>Conclusions: </strong>CXCR4-targeted BG-pSFRT may be a dosimetrically feasible strategy for bulky limited-stage small cell lung cancer and demonstrates distinct dosimetric characteristics. The current research findings are limited to the dosimetric level and further clinical trials are required for verification.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}